(19)
(11) EP 0 774 969 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.07.2003 Bulletin 2003/27

(45) Mention of the grant of the patent:
19.02.2003 Bulletin 2003/08

(21) Application number: 95930118.5

(22) Date of filing: 07.08.1995
(51) International Patent Classification (IPC)7: A61K 31/495, A61K 31/435, A61K 31/425
// (A61K31/495, 31:47),(A61K31/495, 31:435),(A61K31/495, 31:425)
(86) International application number:
PCT/US9509/956
(87) International publication number:
WO 9600/4913 (22.02.1996 Gazette 1996/09)

(54)

HIV PROTEASE INHIBITOR COMBINATION

KOMBINATIONEN VON HIV-PROTEASE INHIBITOREN

COMBINAISON DE L'INHIBITEUR DE LA PROTEASE DU VIH

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
Designated Extension States:
SI

(30) Priority: 11.08.1994 US 289474
14.11.1994 US 339369
20.07.1995 US 492461

(43) Date of publication of application:
28.05.1997 Bulletin 1997/22

(73) Proprietor: Merck & Co., Inc.
Rahway New Jersey 07065-0900 (US)

(72) Inventors:
  • DEUTSCH, Paul, J.
    Rahway, NJ 07065 (US)
  • EMINI, Emilio, A.
    Rahway, NJ 07065 (US)
  • VACCA, Joseph, P.
    Rahway, NJ 07065 (US)

(74) Representative: Cole, William Gwyn et al
European Patent Department, Merck & Co., Inc., Terlings Park, Eastwick Road
Harlow, Essex CM20 2QR
Harlow, Essex CM20 2QR (GB)


(56) References cited: : 
EP-A- 0 346 847
EP-A- 0 541 168
WO-A-92/08700
 EP-A- 0 486 948
WO-A-92/08698
WO-A-94/14436
   
  • PROC NATL ACAD SCI, 26 April 1994 USA, pages 4096-4100, VACCA JP; DORSEY BD; SCHLEIF WA; LEVIN RB; MCDANIEL SL; DARKE PL; ZUGAY J 'L-735,524: an orally bioavailable human immunodeficiency virus type 1'
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).